Vnitr Lek 2019, 65(1):11-12 | DOI: 10.36290/vnl.2019.003

Přímá perorální antikoagulancia u pacientů s nádorovým onemocněním - editorial

Petr Kessler
Oddělení hematologie a transfuziologie, Nemocnice Pelhřimov

Received: July 22, 2018; Published: January 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kessler P. Přímá perorální antikoagulancia u pacientů s nádorovým onemocněním - editorial. Vnitr Lek. 2019;65(1):11-12. doi: 10.36290/vnl.2019.003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Fagarasanu A, Alotaibi GS, Hrimiuc R et al. Role of Extended Thromboprophylaxis After Abdominal and Pelvic Surgery in Cancer Patients: A Systematic Review and Meta-Analysis. Ann Surg Oncol 2016; 23(5): 1422-1430. Dostupné z DOI: http://doi:10.1245/s10434-016-5127-1>. Go to original source... Go to PubMed...
    2. Agnelli G, Gussoni G, Bianchini C et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10(10): 943-949. Dostupné z DOI: <http://dx.doi.org/10.1016/S1470-2045(09)70232-3>. Go to original source... Go to PubMed...
    3. Tun NM, Guevara E, Oo TH. Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Blood Coagul Fibrinolysis 2016; 27(3): 270-274. Dostupné z DOI: <http://dx.doi.org/10.1097/MBC.0000000000000413>. Go to original source... Go to PubMed...
    4. Yu Y, Lv Q, Zhang B et al. Adjuvant therapy with heparin in patients with lung cancer without indication for anticoagulants: A systematic review of the literature with meta-analysis. J Cancer Res Ther 2016; 12(5): 37-42. Go to original source... Go to PubMed...
    5. Hájek R, Maisnar V, Krejčí M et al. Diagnostika a léčba mnohočetného myelomu. Transfuse Hematol dnes 2018; 24(Suppl 1): 5-157.
    6. Palareti G, Legnani C, Lee AYY et al. A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy. Thromb Haemost 2000; 84(5): 805-810. Go to original source... Go to PubMed...
    7. Lee AYY, Levine MN, Baker RI et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349(2): 146-153. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa025313>. Go to original source... Go to PubMed...
    8. Lee AY, Rickles FR, Julian JA et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23(10): 2123-2129. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2005.03.133>. Go to original source... Go to PubMed...
    9. ©mrha J, Kessler P, Poul H et al. Dlouhodobá léčba tromboembolické nemoci u pacientů se zhoubným nádorem. Vnitř Lék 2016; 62(6): 449-452. Go to PubMed...
    10. Raskob GE, van Es N, Verhamme P et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med 2018; 378(7): 615-624. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.